Pfizer Hit With Securities Suit Over Bextra Marketing
Pfizer Inc. was hit Tuesday with another securities fraud class action over its anti-inflammatory drug Bextra, this time being accused of failing to tell investors it was illegally promoting off-label uses...To view the full article, register now.
Already a subscriber? Click here to view full article